As cystic fibrosis (CF) therapies continue to extend life expectancy into the fifth decade and beyond, cystic fibrosis–related diabetes (CFRD) has emerged as one of the most consequential comorbidities affecting this population. CFRD is not merely a metabolic afterthought; it is a unique form of diabetes that accelerates lung function decline, amplifies infection risk, and drives microvascular and macrovascular damage. Understanding the full spectrum of long-term complications—from kidney disease to cardiovascular events—is essential for clinicians, patients, and caregivers. This expanded guide draws on the latest registry data, consensus recommendations, and clinical experience to provide a practical, actionable framework for preventing and managing the lasting consequences of CFRD.

What Makes CFRD Different From Other Diabetes?

CFRD arises from a combination of insulin deficiency and insulin resistance, but its pathophysiology is distinct from type 1 or type 2 diabetes. The underlying defect in the CFTR protein leads to thickened pancreatic secretions that obstruct the ducts, causing progressive fibrosis and fatty replacement of the islets of Langerhans. Over time, beta-cell mass declines, resulting in insufficient insulin secretion. This is compounded by intermittent insulin resistance driven by chronic systemic inflammation, recurrent pulmonary exacerbations, and the frequent use of glucocorticoids.

Unlike type 1 diabetes, endogenous insulin production rarely ceases entirely, so diabetic ketoacidosis is uncommon except under extreme physiological stress. Unlike type 2 diabetes, individuals with CFRD are often lean or malnourished, and insulin resistance is masked by low adiposity. The glycemic pattern is also unique: marked post-prandial hyperglycemia with preserved fasting glucose is typical in early stages, making the oral glucose tolerance test (OGTT) the gold standard for diagnosis. HbA1c is often misleadingly low due to increased red blood cell turnover from chronic inflammation, further complicating screening. Continuous glucose monitoring (CGM) has become increasingly valuable, revealing wide glycemic excursions that standard tests may miss, particularly during nocturnal hours and after high-calorie meals.

Diagnostic Criteria and Screening Recommendations

The Cystic Fibrosis Foundation recommends annual screening with a 2-hour OGTT beginning at age 10 for all people with CF. CFRD is diagnosed when fasting glucose is ≥126 mg/dL, or the 2-hour glucose is ≥200 mg/dL. Because acute illness can transiently elevate glucose, confirmation with a repeat OGTT after recovery is advised. For inpatients, persistent hyperglycemia (fasting ≥126 mg/dL or post-prandial ≥200 mg/dL) lasting more than 48 hours during a pulmonary exacerbation should prompt CFRD evaluation.

CGM is increasingly used to capture glycemic variability and post-prandial spikes that OGTT may miss. CGM also helps distinguish CFRD from stress hyperglycemia and provides data for insulin dose adjustments. Emerging evidence from studies using CGM suggests that even patients with normal OGTT results may spend significant time in hyperglycemic ranges, especially after high-fat, high-carbohydrate meals typical of CF dietary recommendations. This has led some centers to adopt CGM as a routine screening tool for CFRD, though formal guidelines still prioritize OGTT.

Long-Term Complications: An Organ-by-Organ Perspective

Chronic hyperglycemia damages tissues through advanced glycation end-products, oxidative stress, activation of the polyol and protein kinase C pathways, and heightened inflammation. These mechanisms affect the kidneys, eyes, nerves, cardiovascular system, and—most critically—the already compromised lungs. As survival improves, the prevalence of these complications is rising, making proactive screening and early intervention more important than ever. The interplay between CF-specific factors (e.g., chronic infection, malabsorption, hepatobiliary disease) and diabetic complications creates a unique risk profile that requires tailored monitoring.

Diabetic Kidney Disease (Nephropathy)

Persistent hyperglycemia damages the glomerular basement membrane, leading to albuminuria and progressive loss of renal function. In CF, the kidneys face additional insults from repeated courses of aminoglycoside antibiotics (e.g., tobramycin), dehydration during exacerbations, and the nephrotoxic effects of certain CFTR modulators. Registry studies report that 20–30% of adults with CFRD have micro- or macroalbuminuria. End-stage renal disease remains rare but is increasing, particularly in patients with concurrent CF-related kidney disease, such as IgA nephropathy or drug-induced nephritis. Importantly, early kidney dysfunction may be reversible with improved glycemic control, underscoring the need for annual screening.

Screening and management:

  • Annual urine albumin-to-creatinine ratio and estimated GFR starting five years after CFRD diagnosis.
  • Angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) as first-line renoprotective therapy, even in normotensive patients with microalbuminuria.
  • Aminoglycoside trough levels must be monitored closely; alternative antibiotics should be considered when renal function declines.
  • Avoid nephrotoxic combinations such as concurrent vancomycin and piperacillin-tazobactam when possible.

Diabetic Retinopathy and Vision Loss

Elevated glucose damages retinal capillaries, causing microaneurysms, hemorrhages, exudates, and—in advanced stages—proliferative retinopathy with neovascularization that can lead to blindness. In the general diabetic population, retinopathy is a leading cause of preventable vision loss. Among individuals with CFRD, the prevalence ranges from 10–20% after ten years of diabetes duration, which is lower than in type 1 but still clinically significant. Progression is accelerated by hypertension, poor glycemic control, and systemic corticosteroid use—all common in CF. A recent large cohort study found that the risk of proliferative retinopathy in CFRD is comparable to that in type 1 diabetes when adjusted for diabetes duration, highlighting the need for vigilance.

Key recommendations:

  • Annual dilated fundus examination by an ophthalmologist experienced in diabetic retinopathy, even in asymptomatic patients.
  • Laser photocoagulation or intravitreal anti-VEGF injections can halt progression if detected early.
  • Aim for HbA1c <7.0% when safe, but individualized targets are necessary to avoid hypoglycemia. However, because HbA1c underestimates glycemia in CF, use CGM metrics such as time-in-range (70–180 mg/dL) as a more reliable treatment target.
  • Pregnancy in women with CFRD requires even more intensive ophthalmologic monitoring due to accelerated retinopathy risk.

Diabetic Neuropathy: Peripheral and Autonomic

Chronic hyperglycemia damages peripheral and autonomic nerves. The most common manifestation is distal symmetric polyneuropathy, presenting with numbness, tingling, burning pain, or loss of sensation in a stocking-glove distribution. Autonomic neuropathy can affect the gastrointestinal tract (gastroparesis), bladder function, cardiovascular reflexes, and sweating. In CF, autonomic dysfunction may exacerbate existing malabsorption and distal intestinal obstruction syndrome. Subclinical neuropathy detected by nerve conduction studies affects 30–40% of adults with CFRD. Autonomic neuropathy, in particular, can worsen CF-related gastroparesis and lead to unpredictable glucose absorption, creating a vicious cycle of post-prandial hyperglycemia and late hypoglycemia.

Management strategies:

  • Annual monofilament testing and vibration perception threshold screening.
  • For painful neuropathy, gabapentin, pregabalin, or duloxetine are preferred; tricyclic antidepressants should be avoided in patients with constipation or cardiac arrhythmia risk.
  • For gastroparesis, consider prokinetic agents (metoclopramide, erythromycin) and small, frequent, low-fat meals to improve gastric emptying. In severe cases, gastric electrical stimulation may be considered.
  • Assess for orthostatic hypotension with blood pressure measurements supine and standing; advise adequate hydration and compression stockings if positive.

Pulmonary Complications: The Most Critical Consequence

The lung is arguably the organ most vulnerable to the long-term effects of CFRD. Hyperglycemia impairs neutrophil chemotaxis, phagocytosis, and intracellular bacterial killing, making the CF airway more susceptible to infection with Pseudomonas aeruginosa, Staphylococcus aureus, and Burkholderia cepacia complex. Chronic hyperglycemia also promotes a pro-inflammatory milieu, accelerating the decline in forced expiratory volume in one second (FEV1). Hyperglycemia directly impairs mucociliary clearance and increases airway surface liquid glucose concentration, providing a substrate for bacterial growth.

Multiple cohort studies have shown that the onset of CFRD is associated with a more rapid decline in lung function. For example, a 2021 analysis of the U.S. CF Foundation Patient Registry found that patients with CFRD had a 30% higher risk of hospitalization for pulmonary exacerbations and a faster annual FEV1 decline (3–5% per year versus 1–2% in those without diabetes). Importantly, insulin therapy that lowers blood glucose has been shown to reduce sputum bacterial density and slow lung function decline, underscoring the direct link between glycemic control and respiratory health. More recent data suggest that achieving a time-in-range >70% with CGM-guided insulin therapy can stabilize FEV1 over 12 months, even in patients with advanced lung disease.

Clinical implications:

  • Screen for CFRD early and treat with insulin, not oral agents, to leverage the anabolic effects of insulin on muscle and respiratory function.
  • During acute exacerbations, increase insulin doses as needed (often 2–3-fold) and use frequent monitoring (every 2–4 hours) to maintain target glucose levels. Consider initiating an insulin drip for critically ill patients.
  • CFTR modulator therapies (ivacaftor, tezacaftor, elexacaftor) may delay or improve CFRD in some patients, though evidence is still accumulating. Monitor glucose closely after starting modulators, as some patients experience rapid improvement in insulin secretion while others develop paradoxical hyperglycemia due to increased calorie absorption.
  • Encourage pulmonary rehabilitation and exercise; physical activity improves insulin sensitivity and may help preserve lung function.

Cardiovascular Disease and Macrovascular Risk

Cardiovascular disease has historically been underappreciated in CF because of early mortality. With median survival now exceeding 50 years, myocardial infarction, stroke, and heart failure are increasingly reported. Chronic hyperglycemia accelerates atherosclerosis through endothelial dysfunction, lipid oxidation, and arterial stiffness. Systemic inflammation in CF further promotes a pro-thrombotic state. A 2020 registry analysis found that adults with CFRD had a 40% higher risk of composite cardiovascular events (coronary artery disease, stroke, peripheral arterial disease) compared to those without diabetes, after adjusting for age, CFTR genotype, and lung function. Notably, the calcification pattern in CF-related coronary artery disease may differ, with heavy coronary artery calcium scores even in younger patients.

Preventive measures:

  • Measure blood pressure and fasting lipid profile annually. Initiate statin therapy for LDL >100 mg/dL or in patients over 40 years of age with CFRD. Consider a lower threshold in patients with multiple risk factors.
  • Smoking cessation is critical; tobacco use compounds both microvascular and macrovascular risk.
  • Encourage regular physical activity as tolerated to improve insulin sensitivity and cardiovascular fitness.
  • Assess 10-year ASCVD risk using the pooled cohort equations; however, these equations may underestimate risk in CF due to competing risks. Consider coronary artery calcium scoring for intermediate-risk patients.
  • Monitor for heart failure symptoms, especially in patients on CFTR modulators that may cause fluid shifts and increased cardiac demand.

Other Emerging Complications

Bone disease: CF patients already have high rates of osteoporosis due to vitamin D deficiency, glucocorticoid use, and physical inactivity. CFRD adds impairment of osteoblast function and increased urinary calcium excretion, elevating fracture risk—especially in the spine and ribs. DXA screening every 2–3 years is recommended for all adults with CFRD. Bisphosphonate therapy should be considered for those with T-score < -2.5 or history of fragility fracture, with careful monitoring for renal function and atypical femur fractures.

Hepatic complications: CFRD is associated with an increased prevalence of non-alcoholic fatty liver disease and CF-related liver disease. Chronic hyperglycemia promotes steatosis and fibrosis; liver function tests and annual abdominal ultrasound are prudent. Transient elastography (FibroScan) can help quantify liver fibrosis and is increasingly used in CF clinics. In patients with cirrhosis, insulin dosing requires careful adjustment due to altered gluconeogenesis and risk of hypoglycemia.

Nutritional decline: Uncontrolled diabetes leads to catabolic wasting, exacerbating the protein-energy malnutrition common in CF. Insulin therapy not only controls glucose but also restores anabolic balance, helping to maintain or improve body mass index. However, the high-calorie CF diet can make glycemic control challenging; collaboration with a CF-specialized dietitian is essential to ensure adequate calorie intake while optimizing carbohydrate distribution.

Infectious complications: CFRD increases susceptibility to nontuberculous mycobacteria (NTM) infection, likely due to immune dysfunction. Screening for NTM should be performed annually with sputum cultures, and glycemic optimization should be a priority in patients with NTM disease.

Proactive Management of Long-Term Risk

Preventing complications requires an integrated approach that weaves diabetes care into the fabric of CF pulmonary and nutritional management. The Cystic Fibrosis Foundation, in collaboration with the American Diabetes Association, has published consensus guidelines tailored to the unique aspects of CFRD. The model of "CF endocrine comanagement" — where an endocrinologist or specialized nurse practitioner sees patients during routine CF clinic visits — has been shown to improve glycemic outcomes, reduce hospitalizations, and enhance patient satisfaction.

Glycemic Targets and Monitoring Technologies

An HbA1c goal of <7.0% is recommended for most adults, but targets must be individualized. Because HbA1c is often falsely low in CF due to increased red blood cell turnover, self-monitoring of blood glucose (SMBG) and CGM are preferred for treatment decisions. Pre-meal glucose targets are 90–130 mg/dL, and post-meal targets are <180 mg/dL. Hypoglycemia (<70 mg/dL) should be avoided, especially in those with gastroparesis or inconsistent caloric intake. Time-in-range (70–180 mg/dL) of >70% is a practical CGM goal, with time below range <4%.

  • Perform SMBG at least four times daily: before meals and at bedtime. Post-prandial checks (1–2 hours after meals) are essential for insulin dose adjustments.
  • CGM (e.g., Dexcom G6, FreeStyle Libre 3) captures glycemic patterns, reduces fingerstick burden, and detects nocturnal hypoglycemia and post-prandial spikes that SMBG may miss. The advent of factory-calibrated, needle-free CGM has improved adherence.
  • Annual OGTT screening should continue even after diagnosis to reassess glycemic status and insulin requirements. In patients with established CFRD, the OGTT can help differentiate persistent from stress-induced hyperglycemia.
  • Consider using CGM-based metrics like glucose management indicator (GMI) as an alternative to HbA1c for monitoring long-term control.

Insulin Therapy: The Cornerstone of CFRD Management

Insulin is the only recommended pharmacologic therapy for CFRD. Metformin is contraindicated due to risk of lactic acidosis and lack of efficacy in insulin-deficient states. Sulfonylureas and other oral agents are generally ineffective and increase hypoglycemia risk. Insulin regimens must accommodate the high-calorie, high-carbohydrate diets needed to maintain weight. Approximately 50–70% of CFRD patients can be managed with mealtime rapid-acting insulin alone (prandial regimen), especially in early stages when fasting hyperglycemia is absent. As beta-cell function declines, a basal-bolus approach becomes necessary.

  • Basal-bolus regimens (long-acting insulin once daily plus rapid-acting insulin before meals) offer flexible and effective control. Long-acting analogs such as insulin degludec or glargine U300 provide stable basal coverage with lower hypoglycemia risk.
  • Insulin pump therapy (continuous subcutaneous insulin infusion) is an option for motivated patients, providing precise dose adjustments and reduced hypoglycemia. Automated insulin delivery systems (hybrid closed-loop) are being studied in CFRD and show promise for improving time-in-range.
  • Carbohydrate counting taught by a CF-specialized dietitian helps patients match insulin doses to meals that are often high in fat and calories. Because CF meals are calorically dense, advanced bolus options (dual-wave or square-wave) on pumps or smart pens can help cover the delayed post-prandial glycemic peak.
  • During pulmonary exacerbations, insulin requirements may increase 2- to 3-fold; frequent monitoring and dose titration are critical. Use insulin sliding scales or correction algorithms to avoid prolonged hyperglycemia. After recovery, insulin doses should be reduced to prevent hypoglycemia.

Multidisciplinary Care and Integrated Follow-Up

Optimal CFRD management requires a team including the CF pulmonologist, endocrinologist, diabetes educator, dietitian, social worker, and pharmacist. Coordinating diabetes care with routine CF clinic visits improves adherence and outcomes. The CF endocrine clinic model—where diabetes care is delivered alongside pulmonary care—has been shown to enhance glycemic control and reduce complication rates. Quarterly visits allow for timely insulin adjustments and complication screening.

An integrated follow-up schedule includes:

  • Quarterly diabetes visits with review of SMBG/CGM data, HbA1c (interpreted cautiously), insulin dose adjustments, and nutritional assessment. Body weight and BMI should be tracked to detect catabolic states early.
  • Annual screening for microvascular complications (albuminuria, retinopathy, neuropathy) beginning five years after CFRD diagnosis. For retinopathy, start screening after 3–5 years of diabetes or at age 18, whichever comes first.
  • Bone density (DXA) every 2–3 years in adults; more frequently if on chronic glucocorticoids or with history of fractures.
  • Cardiovascular risk assessment with blood pressure, lipids, and 10-year ASCVD risk score; initiate statin and antihypertensive therapy as indicated. Consider electrocardiogram and echocardiogram at baseline in patients over age 40.
  • Psychosocial support for diabetes distress, food-related guilt, and the burden of managing multiple chronic illnesses. Peer support groups and mental health referrals can improve quality of life. Screening for depression and anxiety is recommended annually.

Role of CFTR Modulators in CFRD

CFTR modulator therapies (ivacaftor, lumacaftor, tezacaftor, elexacaftor) have transformed CF care by restoring some CFTR function. Emerging evidence suggests that modulators may improve insulin secretion and glucose tolerance in some patients, possibly by reducing pancreatic inflammation and preserving beta-cell mass. However, the effect is variable and not all patients experience glycemic improvement. Additionally, modulators can affect insulin clearance and appetite, leading to weight gain that may necessitate insulin dose adjustments. Close glucose monitoring after starting a modulator is essential, with CGM recommended for the first 3 months. Interestingly, some patients on elexacaftor-tezacaftor-ivacaftor have developed new-onset hyperglycemia, possibly due to increased pancreatic islet workload from restored insulin secretion. A paradoxical phenomenon of worsening glucose tolerance can occur in the first 6 months, followed by improvement later. Thus, insulin doses may need to be both increased and later reduced.

External Resources for Patients and Providers

By integrating these strategies into routine care, clinicians can help people with CFRD live longer, healthier lives with fewer complications. The goal is not just to manage blood glucose, but to preserve lung function, protect microvascular health, and support overall well-being. With early detection, aggressive insulin therapy, and a coordinated multidisciplinary approach—enhanced by emerging technologies like CGM and automated insulin delivery—the long-term outlook for individuals with CFRD continues to improve. Ongoing research into the effects of CFTR modulators on pancreatic function and the development of CF-specific risk prediction tools will further refine management and reduce the burden of this challenging comorbidity.